Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors

touchPANEL DISCUSSION for touchNEUROLOGY Listen to two expert neurologists and a neurology nurse as they explore the role of neonatal Fc receptor (FcRn) inhibitors in improving the burden of disease in patients with generalized myasthenia gravis. The faculty will consider how the burden of disease and treatment in patients with generalized myasthenia gravis can be used to inform treatment decisions, the latest clinical data for FcRn inhibitors and the best practice strategies for using FcRn inhibitors in clinical practice.  The experts Prof. Michael Nicolle – Western University and London Health Sciences Centre, London, ON, Canada Dr Karissa Gable – Duke University, Durham, NC, USA Ms Missy Pittman – Duke University, Durham, NC, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Argenx and UCB, Inc.  The activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchneurologyime.org/reducing-burden-of-disease-in-gmg-exploring-the-role-of-fcrn-inhibitors/